Robert Routh, MD
Ophthalmology · New Smyrna Beach, FLNPI 1992932776
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,070 of the $1,346 with a category attached, or 79.5%. 16 manufacturers reported payments, led by Rxsight Inc at 26.8% of the total. Reporting peaked in 2022 at $399 and has fallen 67.0% since, to $132 in 2025. That places this record below the midpoint for ophthalmology clinicians in FL, where the typical reported total is $1,824.
Across 52 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$360
- Ocular Therapeutix, Inc.$251
- Alcon$195
- Glaukos Corporation$102
- Sun Pharmaceutical Industries Inc.$87
- Heru, Inc.$68
- plus $283 from 10 others
Across 9 payments — averaging $157.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$1K
What the payments were for
- Consulting fees$25019%
- Speaking & faculty fees$262%
- Food & beverage$1,07080%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 5 | $360 |
| Ocular Therapeutix, Inc. | 14 | $251 |
| Alcon | 8 | $195 |
| Glaukos Corporation | 4 | $102 |
| Sun Pharmaceutical Industries Inc. | 4 | $87 |
| Heru, Inc. | 1 | $68 |
| AbbVie(2 entities) | 4 | $67 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $39 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $33 |
| Sight Sciences, Inc. | 2 | $30 |
| Dompe US, Inc. | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Omeros Corporation | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Eyepoint US, Inc. | 1 | $18 |
| Oyster Point Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,346 in reported general payments places this provider in the 40th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 19 | $27,842 |
| VyzultaLatanoprostene Bunod | 18 | $12,233 |
| Prednisolone Acetate | 287 | $11,051 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $9,905 |
| RhopressaNetarsudil Mesylate | 16 | $7,242 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $7,139 |
| Latanoprost | 469 | $6,654 |
| Timolol Maleate | 232 | $3,467 |
| Cyclosporine | 13 | $3,267 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 19 | $2,730 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $2,650 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 133 | $2,476 |
| Travoprost | 20 | $2,117 |
| Fluorometholone | 33 | $1,464 |
| Brimonidine Tartrate | 104 | $1,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $67 | $34,98135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in New Smyrna Beach
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.